DANAPAROID: 170 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
170
Total FAERS Reports
67 (39.4%)
Deaths Reported
75
Hospitalizations
170
As Primary/Secondary Suspect
21
Life-Threatening
1
Disabilities
Dec 24, 1996
FDA Approved
Discontinued
Status
Active Ingredient: DANAPAROID SODIUM · FDA Application: 020430 ·
First Report: 201103 · Latest Report: 20240101
What Are the Most Common DANAPAROID Side Effects?
#1 Most Reported
Heparin-induced thrombocytopenia
27 reports (15.9%)
#2 Most Reported
Shock haemorrhagic
14 reports (8.2%)
#3 Most Reported
Acute kidney injury
14 reports (8.2%)
All DANAPAROID Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Heparin-induced thrombocytopenia | 27 | 15.9% | 8 | 19 |
| Acute kidney injury | 14 | 8.2% | 11 | 3 |
| Shock haemorrhagic | 14 | 8.2% | 11 | 2 |
| Haematoma | 12 | 7.1% | 9 | 4 |
| Thrombocytopenia | 12 | 7.1% | 3 | 5 |
| Off label use | 11 | 6.5% | 2 | 8 |
| Deep vein thrombosis | 10 | 5.9% | 2 | 7 |
| International normalised ratio increased | 10 | 5.9% | 7 | 3 |
| Anaemia | 9 | 5.3% | 0 | 8 |
| Haemorrhage | 9 | 5.3% | 5 | 0 |
| Maternal exposure during pregnancy | 9 | 5.3% | 0 | 0 |
| Rectal haemorrhage | 9 | 5.3% | 1 | 8 |
| Cerebral haemorrhage | 8 | 4.7% | 8 | 2 |
| Stevens-johnson syndrome | 8 | 4.7% | 8 | 0 |
| Condition aggravated | 7 | 4.1% | 1 | 6 |
| Drug ineffective | 7 | 4.1% | 4 | 2 |
| Therapeutic product cross-reactivity | 7 | 4.1% | 1 | 5 |
| Exposure during pregnancy | 5 | 2.9% | 0 | 0 |
| Foetal exposure during pregnancy | 5 | 2.9% | 0 | 0 |
| Haemorrhagic anaemia | 5 | 2.9% | 1 | 4 |
Who Reports DANAPAROID Side Effects? Age & Gender Data
Gender: 63.1% female, 36.9% male. Average age: 63.4 years. Most reports from: FR. View detailed demographics →
Is DANAPAROID Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2011 | 3 | 1 | 2 |
| 2012 | 3 | 3 | 0 |
| 2013 | 3 | 1 | 3 |
| 2014 | 14 | 6 | 8 |
| 2015 | 14 | 2 | 12 |
| 2016 | 5 | 2 | 4 |
| 2017 | 6 | 2 | 3 |
| 2018 | 18 | 10 | 9 |
| 2019 | 7 | 1 | 6 |
| 2020 | 3 | 0 | 3 |
| 2021 | 7 | 1 | 6 |
| 2022 | 4 | 2 | 1 |
| 2023 | 13 | 8 | 5 |
| 2024 | 4 | 0 | 0 |
What Is DANAPAROID Used For?
| Indication | Reports |
|---|---|
| Product used for unknown indication | 50 |
| Heparin-induced thrombocytopenia | 34 |
| Thrombosis prophylaxis | 22 |
| Anticoagulant therapy | 18 |
| Pulmonary embolism | 15 |
| Thrombocytopenia | 5 |
DANAPAROID vs Alternatives: Which Is Safer?
DANAPAROID vs DANAZOL
DANAPAROID vs DANICOPAN
DANAPAROID vs DANTROLENE
DANAPAROID vs DAPAGLIFLOZIN
DANAPAROID vs DAPAGLIFLOZIN PROPANEDIOL
DANAPAROID vs DAPAGLIFLOZIN PROPANEDIOL\METFORMIN
DANAPAROID vs DAPRODUSTAT
DANAPAROID vs DAPSONE
DANAPAROID vs DAPTOMYCIN
DANAPAROID vs DARATUMUMAB
Official FDA Label for DANAPAROID
Official prescribing information from the FDA-approved drug label.